Compare ATYR & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATYR | ASRT |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.2M | 76.0M |
| IPO Year | N/A | 2004 |
| Metric | ATYR | ASRT |
|---|---|---|
| Price | $0.85 | $11.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | $4.20 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 1.4M | 24.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 95.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $124,961,000.00 |
| Revenue This Year | $9,628.95 | N/A |
| Revenue Next Year | $156.94 | $1.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.64 | $0.51 |
| 52 Week High | $7.29 | $12.95 |
| Indicator | ATYR | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 50.67 |
| Support Level | $0.82 | $11.05 |
| Resistance Level | $0.85 | $12.45 |
| Average True Range (ATR) | 0.07 | 0.46 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 7.78 | 38.46 |
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.